National Medical Products Administration: Optimization of related matters in the review and approval of clinical trials for innovative drugs.

According to the Zhitong Finance APP, on September 12, the National Medical Products Administration issued the "Notice on Optimizing the Evaluation and Approval of Clinical Trials for Innovative Drugs", which pointed out that in order to further support innovative drug research and development guided by clinical value, and improve the quality and effectiveness of clinical research and development, the evaluation and approval of clinical trial applications for eligible innovative drugs will be completed within 30 working days after acceptance. The 30-day fast track for the evaluation and approval of clinical trials for innovative drugs supports national key research and development varieties, encourages early simultaneous global research and international multicenter clinical trials, and serves clinical needs and the development of the national pharmaceutical industry.